Previous 10 | Next 10 |
home / stock / bctxf / bctxf news
BERKELEY, Calif., and VANCOUVER, British Columbia, Nov. 17, 2020 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (" BriaCell " or the "Company") (TSX-V:BCT) (OTCQB:BCTXF) , a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast ...
BriaCell and National Cancer Institute to collaborate on Bria- OTS ™ , BriaCell’s off-the-shelf personalized immunotherapy, as a treatment for cancer . BERKELEY, Calif., and VANCOUVER, British Columbia, Nov. 10, 2...
Overall Survival of 13. 3 months in patients , including 14 months in patients with Grade I/II tumors , suggesting clinical benefit; Comparison: 7. 2 -9. 8 months in similar p...
BERKELEY, Calif., and VANCOUVER, British Columbia, Oct. 06, 2020 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (" BriaCell " or the "Company") (TSX-V:BCT) (OTCQB:BCTXF ) , a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast...
BERKELEY, Calif., and VANCOUVER, British Columbia, Oct. 01, 2020 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (" BriaCell " or the "Company") (TSX-V:BCT) (OTCQB:BCTXF) is a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast can...
BERKELEY, Calif. and VANCOUVER, British Columbia, Sept. 15, 2020 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced ...
BERKELEY, Calif. and VANCOUVER, British Columbia, Sept. 04, 2020 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced ...
BERKELEY, Calif. and VANCOUVER, British Columbia, Aug. 17, 2020 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF) , a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, announces that...
Preliminary safety and efficacy data are being presented today from the clinical trials of Bria-IMT™ in combination with immune checkpoint (PD-1) inhibitors in advanced breast cancer patients. Clinical responses and disease control—without serious side effects—...
BERKELEY, Calif. and VANCOUVER, British Columbia, Aug. 11, 2020 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF) , a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, announces that...
News, Short Squeeze, Breakout and More Instantly...
BriaCell Therapeutics Company Name:
BCTXF Stock Symbol:
OTCMKTS Market:
Clinical and pathological findings from clinical trial of the Bria-IMT™ regimen alone and in combination with immune checkpoint inhibitors in advanced breast cancer will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2021, April 10-15 and May...
BERKELEY, Calif. and VANCOUVER, British Columbia, Feb. 26, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (TSX-V:BCT) (NASDAQ: BCTX, BCTXW) (“BriaCell” or the “Company”) , a clinical-stage biotechnology company specializing in targeted immunotherapies f...
BERKELEY, Calif. and VANCOUVER, British Columbia, Feb. 23, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (TSX-V:BCT) (NASDAQ: BCTX, BCTXW) (“BriaCell” or the “Company”) , a clinical-stage biotechnology company specializing in targeted immunotherapies f...